Comparison of Lipid-Lowering Effects of Anagliptin and Miglitol in Patients With Type 2 Diabetes: A Randomized Trial

BACKGROUND: Recently, we reported that the level of lathosterol, a cholesterol synthesis marker, was suppressed after 1 month of treatment with anagliptin, a dipeptidyl peptidase-4 inhibitor. In this study, we administered either anagliptin or miglitol, an alpha-glucosidase inhibitor, for 3 months i...

Descripción completa

Detalles Bibliográficos
Autores principales: Iijima, Takahiro, Aoki, Kazutaka, Kondo, Yoshinobu, Terauchi, Yasuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011936/
https://www.ncbi.nlm.nih.gov/pubmed/32095176
http://dx.doi.org/10.14740/jocmr4084

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011936/
https://www.ncbi.nlm.nih.gov/pubmed/32095176
http://dx.doi.org/10.14740/jocmr4084

Ejemplares similares